Dr. Yan Leyfman has been recognized as one of the top international researchers in oncology by the American Society of Hematology and American Society of Clinical Oncology (ASCO). He has contributed to the development of several anti-cancer therapies that have recently entered clinical trials and new treatment recommendations of care. His successes have been recognized by the Goldwater Research Foundation, Sigma Xi, New York Times, ABC, and Harvard Medical School. During the COVID-19 pandemic, he was recruited as the Director of the Immunology Division of the Global COVID-19 Taskforce, which produced one of the first mechanisms for SARS-CoV-2, COVI-Flu, and cancer & COVID along with elucidating the mechanism of a promising cellular therapy against COVID-19 that received US FDA fast track designation in December 2020. His work has been published as the cover article in the journal, Shock, and in the textbook, Insights on a Post-COVID World. Over the past two years, Dr. Leyfman was recognized as the 2020 iCHEM Emerging International Scholar in Immunology & Immunotherapy, 2020 New York State & City Manhattan Hero, 2021 Lymphoma, Leukemia & Myeloma Congress Hero in Healthcare, and by Memorial Sloan Kettering Cancer Center for research excellence.
Dr. Leyfman also has a passion for mentorship and community service. He is a journal editor and mentor to medical students globally and gives talks about the latest innovations in medicine. Dr. Leyfman has a passion for correcting medical misinformation, medical education, and combating healthcare inequity and has co-founded MedNews Week, a global mainstream platform where he and his team puts on weekly shows and hosts Keynote Conferences by global leaders in medicine.
